Evidence map›Paper›PMID 23084371›Full record

ArticleImmunobiology2013

Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis.

Kenneth Smith, Jennifer J Muther, Angie L Duke, Emily McKee, Nai-Ying Zheng, Patrick C Wilson, Judith A James

Abstract read
In one paragraph

Article in Immunobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kenneth SmithOklahoma Medical Research Foundation, Arthritis and Clinical Immunology Research Program, Oklahoma City, OK 73104, USA. smithk@omrf.org
Jennifer J Muther
Angie L Duke
Emily McKee
Nai-Ying Zheng
Patrick C Wilson
Judith A James
Oklahoma Medical Research Foundation · USUniversity of Chicago · USUniversity of Oklahoma Health Sciences Center · US

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK · 2004 to 2023
$56.2M
THE EFFECTS OF ERK PATHWAY INHIBITION ON DNA METHYLATION IN SLEP20RR015577 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI DRESSER, MICHAEL EDWARD · 2000 to 2009
$21.5M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
Science in a Culture of MentoringP30GM103510 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$3.9M
Science in a Culture of MentoringP30RR031152 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2010 to 2011
$2.4M
IMMUNE FUNCTION AND BIODEFENSE IN CHILDREN ELDERLY AND IMMUNOCOMPROMIS-266050026N01AI050026 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA · 2006 to 2006
–
NCRR NIH HHS P20 RR015577NCRR NIH HHS P20RR015577NCRR NIH HHS P20RR01557710S1NCRR NIH HHS P30 RR031152NIAID NIH HHS HHSN266200500026CNIAID NIH HHS N01 AI050026NIAID NIH HHS N01-AI500026NIAID NIH HHS U19 AI062629NIAID NIH HHS U19AI062629NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P30AR053483NIGMS NIH HHS P30 GM103510NIGMS NIH HHS P30RR031152/P30GM103510
6 · The paper itself

Abstract

B lymphocyte memory generates antibody-secreting cells (ASCs) that represent a source of protective antibodies that may be exploited for therapeutics. Here we vaccinated four donors with Pneumovax®23 and produced human monoclonal antibodies (hmAbs) from ASCs. We have cloned 137 hmAbs and the specificities of these antibodies encompass 19 of the 23 serotypes in the vaccine, as well as cell wall polysaccharide (CWPS). Although the majority of the antibodies are serotype specific, 12% cross-react with two serotypes. The Pneumovax®23 ASC antibody sequences are highly mutated and clonal, indicating an anamnestic response, even though this was a primary vaccination. Hmabs from 64% of the clonal families facilitate opsonophagocytosis. Although 9% of the total antibodies bind to CWPS impurity in the vaccine, none of these clonal families showed opsonophagocytic activity. Overall, these studies have allowed us to address unanswered questions in the field of human immune responses to polysaccharide vaccines, including the cross-reactivity of individual antibodies between serotypes and the percentage of antibodies that are protective after vaccination with Pneumovax®23.

Indexed as

Antibodies, BacterialAntibodies, MonoclonalAntibody-Producing CellsAntibody SpecificityClone CellsCross ReactionsFemaleHL-60 CellsHumansImmunologic MemoryMaleMiddle AgedOpsonin ProteinsPhagocytosisPneumococcal InfectionsPneumococcal VaccinesAntibodies, BacterialAntibodies, MonoclonalOpsonin ProteinsPneumococcal VaccinesPolysaccharides, Bacterial

Identifiers

PMID23084371
PMCPMC3556204
OpenAlexW2061331393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.